Tselis A, Perumal J, Caon C, Hreha S, Ching W, Din M, Van Stavern G, Khan O
Department of Neurology, Multiple Sclerosis Clinical Research Center, Detroit, MI, USA.
Eur J Neurol. 2008 Nov;15(11):1163-7. doi: 10.1111/j.1468-1331.2008.02258.x. Epub 2008 Aug 21.
Patients with severe visual loss because of optic neuritis refractory to high dose corticosteroids have limited therapeutic options. The use of intravenous immunoglobulin (IVIG) has been advocated in the past, but data are scarce. In this study, we use a protocol different from those used in other studies, with different timing and dosage.
Consecutive patients with corticosteroid-refractive optic neuropathy were treated with IVIG and compared with control patients who received only corticosteroids in an open-label, non-randomized, controlled prospective study.
Twenty-three patients received treatment with IVIG and 24 matched patients who did not receive treatment with IVIG were followed as controls. All patients had visual acuity 20/400 or worse in the affected eye. There was significant improvement in the IVIG group with 18/23 (78%) subjects reaching near normal vision (20/30 or better), compared with the control group with only 3/24 (12.5%) responding similarly.
The use of IVIG, following corticosteroids, may be useful using the protocol described herein, with sustained pulsed dosing. A larger controlled trial is indicated to confirm these results.
因高剂量皮质类固醇治疗无效而导致严重视力丧失的视神经炎患者,治疗选择有限。过去曾提倡使用静脉注射免疫球蛋白(IVIG),但数据稀少。在本研究中,我们采用了与其他研究不同的方案,包括不同的时间安排和剂量。
在一项开放标签、非随机、对照前瞻性研究中,对连续的皮质类固醇难治性视神经病变患者使用IVIG进行治疗,并与仅接受皮质类固醇治疗的对照患者进行比较。
23例患者接受了IVIG治疗,24例匹配的未接受IVIG治疗的患者作为对照进行随访。所有患者患眼视力均为20/400或更差。IVIG组有显著改善,18/23(78%)的受试者视力接近正常(20/30或更好),而对照组只有3/24(12.5%)有类似反应。
按照本文所述方案,在皮质类固醇治疗后使用IVIG,并采用持续脉冲给药,可能是有效的。需要进行更大规模的对照试验来证实这些结果。